We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

ROP:NASDAQRoper Technologies, Inc. Analysis

Data as of 2026-08-25 - not real-time

$413.37

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Roper Technologies, Inc. is priced at $413.37, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has gained 19.2%. With RSI at 65.6 the momentum picture is approaching overbought, alongside a bullish MACD signal. Recent trading has carved out support near $381.28 and resistance around $418.75.
Multiples put this in undervalued territory: 17.2 times earnings against the sector's 34.9. Consensus targets land 7.7% above where the shares trade now. Revenue is growing at 8.5% on a 30.2% profit margin. The 0.88% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 5 — moderate. With 30-day volatility of 37.9%, a beta of 0.04 and a maximum drawdown of 40.3%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
All three time horizons resolve to buy, carrying 7/10 conviction.

Top Market Events

SARASOTA, Fla., Aug. 06, 2026 GLOBE NEWSWIRE -- Roper Technologies, Inc. Nasdaq: ROP announced that its Board of...SARASOTA, Fla., Aug. 04, 2026 GLOBE NEWSWIRE -- Roper Technologies, Inc. Nasdaq: ROP announced that it is presenting at...SARASOTA, Fla., Aug. 04, 2026 GLOBE NEWSWIRE -- Roper Technologies, Inc. Nasdaq: ROP announced that it is presenting at...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Trading above the 200-day average of 377.26
  • MACD momentum is positive
  • 30-day price change of +19.2%

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • P/E of 17.2 versus sector average of 34.9
  • Trading above the 200-day average of 377.26
  • Analyst targets imply +7.7% versus the current price

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • P/E of 17.2 versus sector average of 34.9
  • Analyst targets imply +7.7% versus the current price
  • Profit margin of 30.2% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth8.50%
Profit Margin30.24%
P/E Ratio17.2
ROE13.07%
ROA4.23%
Debt/Equity60.53
P/B Ratio2.2
Op. Cash Flow$2.7B
Free Cash Flow$2.3B
Industry P/E34.9

Technical Analysis

TrendNeutral
RSI65.6
Support$381.28
Resistance$418.75
MA 20$400.31
MA 50$370.04
MA 200$377.26
MACDBullish
VolumeDecreasing
Fear & Greed Index93.84

Valuation

Fair Value$308.76
Target Price$445.20
Upside/Downside7.70%
GradeUndervalued
TypeBlend
Dividend Yield0.88%

Risk Assessment

Beta0.04
Volatility37.90%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.